Trial
NCT05268003
A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
M.D. Anderson Cancer Center
Collaborators
—
Condition
Acute Lymphoblastic Leukemia
Intervention
Ponatinib
Why stopped
\< 75% participation
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-27